Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 20, 2025Oncology

Real-World Comparative Analysis of Polatuzumab Vedotin–Based Pola-R-CHP Versus Standard R-CHOP in Diffuse Large B-Cell Lymphoma: A Propensity Score–Matched Cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZiqian WangCWChong WeiKSKai-Ni Shen

Discussion

Loading...

Member takes

Overview

Comparative analysis reveals Pola-R-CHP improves treatment response in DLBCL, highlighting similar safety profiles to R-CHOP.

Key Points

  • The aim was to assess the efficacy and safety of Pola-R-CHP versus R-CHOP for DLBCL treatment.
  • Retrospective analysis of 505 DLBCL patients treated between January 2011 and March 2025.
  • Matched 36 Pola-R-CHP patients and 36 R-CHOP patients using propensity score matching on key characteristics.
  • Evaluated treatment outcomes including complete response, overall survival, and adverse events.
  • Pola-R-CHP demonstrated a higher interim complete response rate (72.2% vs. 63.9%) and overall response rate (100% vs. 83.3%).
  • At the end of treatment, complete response improved to 88.9% for Pola-R-CHP compared to 63.9% for R-CHOP.
  • Higher mortality and progression observed in the R-CHOP group after a median follow-up of 13.3 months.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/6924f074c0ce034ddc34fc3ehttps://doi.org/10.1159/000549477
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative real-world safety outcomes of Pola-R-CHP versus R-CHOP in high-grade diffuse large B-cell lymphoma (DLBCL): A TriNetX study.2026
  2. 2Real-world comparative outcomes of pola-R-CHP versus R-CHOP in patients with diffuse large B-cell lymphoma2025 · 1 citations
  3. 3Real-world outcomes of polatuzumab vedotin plus R-CHP versus R-CHOP in newly diagnosed diffuse large B-cell lymphoma: A propensity-matched analysis.2026
  4. 4Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.2025 · 42 citations
  5. 5Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China2025